Osteoporosis - Pipeline Review, H1 2018
Osteoporosis - Pipeline Review, H1 2018
Summary
Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Osteoporosis - Pipeline Review, H1 2018, provides an overview of the Osteoporosis (Metabolic Disorders) pipeline landscape.
Osteoporosis, or thinning bones, makes bones weak and more likely to break. Risk factors for osteoporosis include aging, being female, low body weight, low sex hormones or menopause, smoking, and some medications. Signs and symptoms include back pain, caused by a fractured or collapsed vertebra, loss of height over time, a stooped posture, a bone fracture that occurs much more easily than expected. Prevention and treatment include calcium and vitamin D, exercise, and osteoporosis medications.
Report Highlights
Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Osteoporosis - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Osteoporosis (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Osteoporosis (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Osteoporosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 9, 6, 4, 16, 1, 56, 15 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 11 and 14 molecules, respectively.
Osteoporosis (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteoporosis (Metabolic Disorders).
- The pipeline guide reviews pipeline therapeutics for Osteoporosis (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteoporosis (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteoporosis (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteoporosis (Metabolic Disorders)
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteoporosis (Metabolic Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteoporosis (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
Abreos Biosciences Inc
Alvogen Korea Co Ltd
Amgen Inc
Asahi Kasei Corp
BiologicsMD Inc
Bone Biologics Corp
Bristol-Myers Squibb Co
Cadila Healthcare Ltd
Cellmid Ltd
ChoDang Pharm Co Ltd
Chugai Pharmaceutical Co Ltd
Corium International Inc
Daiichi Sankyo Co Ltd
Dong Wha Pharma Co Ltd
ElexoPharm GmbH
Eli Lilly and Co
EndoCeutics Inc
Entera Bio Ltd
Enteris BioPharma Inc
Enzene Biosciences Ltd
Enzo Biochem Inc
Evgen Pharma Plc
Gador SA
GL Pharm Tech Corp
GlycoNex Inc
Hanmi Pharmaceuticals Co Ltd
Haoma Medica Ltd
Huons Global Co Ltd
Immunovo BV
Immunwork Inc
Intas Pharmaceuticals Ltd
Ipsen SA
JHL Biotech Inc
Kaken Pharmaceutical Co Ltd
Lead Discovery Center GmbH
Lotus Pharmaceutical Co Ltd
Lupin Ltd
Luye Pharma Group Ltd
mAbxience SA
Merck & Co Inc
Millendo Therapeutics Inc
NIBEC
Omeros Corp
Oncobiologics Inc
Paras Biopharmaceuticals Finland Oy
Pfenex Inc
PhytoHealth Corp
R Pharm
Ribomic Inc
Richter Gedeon Nyrt
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
Shenzhen Salubris Pharmaceuticals Co Ltd
Shin Poong PharmCo Ltd
Sinil Pharmaceutical Co Ltd
Stelis Biopharma Pvt Ltd
Terpenoid Therapeutics Inc
TSH Biopharm Corporation Ltd
Uni-Bio Science Group Ltd
Viking Therapeutics Inc
Wroclawskie Centrum Badan EIT+ Sp z oo
Yooyoung Pharm Co Ltd
2
Introduction 6
Osteoporosis - Overview 7
Osteoporosis - Therapeutics Development 8
Osteoporosis - Therapeutics Assessment 25
Osteoporosis - Companies Involved in Therapeutics Development 35
Osteoporosis - Drug Profiles 62
Osteoporosis - Dormant Projects 220
Osteoporosis - Discontinued Products 228
Osteoporosis - Product Development Milestones 229
Appendix 238List of Tables
Table 1: Number of Products under Development for Osteoporosis, H1 2018
Table 2: Number of Products under Development by Companies, H1 2018
Table 3: Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 4: Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 5: Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 6: Number of Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 7: Number of Products under Development by Universities/Institutes, H1 2018
Table 8: Products under Development by Companies, H1 2018
Table 9: Products under Development by Companies, H1 2018 (Contd..1), H1 2018
Table 10: Products under Development by Companies, H1 2018 (Contd..2), H1 2018
Table 11: Products under Development by Companies, H1 2018 (Contd..3), H1 2018
Table 12: Products under Development by Companies, H1 2018 (Contd..4), H1 2018
Table 13: Products under Development by Companies, H1 2018 (Contd..5), H1 2018
Table 14: Table 15Products under Development by Universities/Institutes, H1 2018
Table 16: Products under Development by Universities/Institutes, H1 2018 (Contd..1), H1 2018
Table 17: Number of Products by Stage and Target, H1 2018
Table 18: Number of Products by Stage and Target, H1 2018 (Contd..1), H1 2018
Table 19: Number of Products by Stage and Mechanism of Action, H1 2018
Table 20: Number of Products by Stage and Mechanism of Action, H1 2018 (Contd..1), H1 2018
Table 21: Number of Products by Stage and Route of Administration, H1 2018
Table 22: Number of Products by Stage and Molecule Type, H1 2018
Table 23: Osteoporosis - Pipeline by Abreos Biosciences Inc, H1 2018
Table 24: Osteoporosis - Pipeline by Alvogen Korea Co Ltd, H1 2018
Table 25: Osteoporosis - Pipeline by Amgen Inc, H1 2018
Table 26: Osteoporosis - Pipeline by Asahi Kasei Corp, H1 2018
Table 27: Osteoporosis - Pipeline by BiologicsMD Inc, H1 2018
Table 28: Osteoporosis - Pipeline by Bone Biologics Corp, H1 2018
Table 29: Osteoporosis - Pipeline by Bristol-Myers Squibb Co, H1 2018
Table 30: Osteoporosis - Pipeline by Cadila Healthcare Ltd, H1 2018
Table 31: Osteoporosis - Pipeline by Cellmid Ltd, H1 2018
Table 32: Osteoporosis - Pipeline by ChoDang Pharm Co Ltd, H1 2018
Table 33: Osteoporosis - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
Table 34: Osteoporosis - Pipeline by Corium International Inc, H1 2018
Table 35: Osteoporosis - Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Table 36: Osteoporosis - Pipeline by Dong Wha Pharma Co Ltd, H1 2018
Table 37: Osteoporosis - Pipeline by ElexoPharm GmbH, H1 2018
Table 38: Osteoporosis - Pipeline by Eli Lilly and Co, H1 2018
Table 39: Osteoporosis - Pipeline by EndoCeutics Inc, H1 2018
Table 40: Osteoporosis - Pipeline by Entera Bio Ltd, H1 2018
Table 41: Osteoporosis - Pipeline by Enteris BioPharma Inc, H1 2018
Table 42: Osteoporosis - Pipeline by Enzene Biosciences Ltd, H1 2018
Table 43: Osteoporosis - Pipeline by Enzo Biochem Inc, H1 2018
Table 44: Osteoporosis - Pipeline by Evgen Pharma Plc, H1 2018
Table 45: Osteoporosis - Pipeline by Gador SA, H1 2018
Table 46: Osteoporosis - Pipeline by GL Pharm Tech Corp, H1 2018
Table 47: Osteoporosis - Pipeline by GlycoNex Inc, H1 2018
Table 48: Osteoporosis - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Table 49: Osteoporosis - Pipeline by Haoma Medica Ltd, H1 2018
Table 50: Osteoporosis - Pipeline by Huons Global Co Ltd, H1 2018
Table 51: Osteoporosis - Pipeline by Immunovo BV, H1 2018
Table 52: Osteoporosis - Pipeline by Immunwork Inc, H1 2018
Table 53: Osteoporosis - Pipeline by Intas Pharmaceuticals Ltd, H1 2018
Table 54: Osteoporosis - Pipeline by Ipsen SA, H1 2018
Table 55: Osteoporosis - Pipeline by JHL Biotech Inc, H1 2018
Table 56: Osteoporosis - Pipeline by Kaken Pharmaceutical Co Ltd, H1 2018
Table 57: Osteoporosis - Pipeline by Lead Discovery Center GmbH, H1 2018
Table 58: Osteoporosis - Pipeline by Lotus Pharmaceutical Co Ltd, H1 2018
Table 59: Osteoporosis - Pipeline by Lupin Ltd, H1 2018
Table 60: Osteoporosis - Pipeline by Luye Pharma Group Ltd, H1 2018
Table 61: Osteoporosis - Pipeline by mAbxience SA, H1 2018
Table 62: Osteoporosis - Pipeline by Merck & Co Inc, H1 2018
Table 63: Osteoporosis - Pipeline by Millendo Therapeutics Inc, H1 2018
Table 64: Osteoporosis - Pipeline by NIBEC, H1 2018
Table 65: Osteoporosis - Pipeline by Omeros Corp, H1 2018
Table 66: Osteoporosis - Pipeline by Oncobiologics Inc, H1 2018
Table 67: Osteoporosis - Pipeline by Paras Biopharmaceuticals Finland Oy, H1 2018
Table 68: Osteoporosis - Pipeline by Pfenex Inc, H1 2018
Table 69: Osteoporosis - Pipeline by PhytoHealth Corp, H1 2018
Table 70: Osteoporosis - Pipeline by R Pharm, H1 2018
Table 71: Osteoporosis - Pipeline by Ribomic Inc, H1 2018
Table 72: Osteoporosis - Pipeline by Richter Gedeon Nyrt, H1 2018
Table 73: Osteoporosis - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2018
Table 74: Osteoporosis - Pipeline by Shenzhen Salubris Pharmaceuticals Co Ltd, H1 2018
Table 75: Osteoporosis - Pipeline by Shin Poong PharmCo Ltd, H1 2018
Table 76: Osteoporosis - Pipeline by Sinil Pharmaceutical Co Ltd, H1 2018
Table 77: Osteoporosis - Pipeline by Stelis Biopharma Pvt Ltd, H1 2018
Table 78: Osteoporosis - Pipeline by Terpenoid Therapeutics Inc, H1 2018
Table 79: Osteoporosis - Pipeline by TSH Biopharm Corporation Ltd, H1 2018
Table 80: Osteoporosis - Pipeline by Uni-Bio Science Group Ltd, H1 2018
Table 81: Osteoporosis - Pipeline by Viking Therapeutics Inc, H1 2018
Table 82: Osteoporosis - Pipeline by Wroclawskie Centrum Badan EIT+ Sp z oo, H1 2018
Table 83: Osteoporosis - Pipeline by Yooyoung Pharm Co Ltd, H1 2018
Table 84: Osteoporosis - Dormant Projects, H1 2018
Table 85: Osteoporosis - Dormant Projects, H1 2018 (Contd..1), H1 2018
Table 86: Osteoporosis - Dormant Projects, H1 2018 (Contd..2), H1 2018
Table 87: Osteoporosis - Dormant Projects, H1 2018 (Contd..3), H1 2018
Table 88: Osteoporosis - Dormant Projects, H1 2018 (Contd..4), H1 2018
Table 89: Osteoporosis - Dormant Projects, H1 2018 (Contd..5), H1 2018
Table 90: Osteoporosis - Dormant Projects, H1 2018 (Contd..6), H1 2018
Table 91: Osteoporosis - Dormant Projects, H1 2018 (Contd..7), H1 2018
Table 92: Osteoporosis - Discontinued Products, H1 2018List of Figures
Figure 1: Number of Products under Development for Osteoporosis, H1 2018
Figure 2: Number of Products under Development by Companies, H1 2018
Figure 3: Number of Products under Development by Universities/Institutes, H1 2018
Figure 4: Number of Products by Top 10 Targets, H1 2018
Figure 5: Number of Products by Stage and Top 10 Targets, H1 2018
Figure 6: Number of Products by Mechanism of Actions, H1 2018
Figure 7: Number of Products by Stage and Mechanism of Actions, H1 2018
Figure 8: Number of Products by Top 10 Routes of Administration, H1 2018
Figure 9: Number of Products by Stage and Top 10 Routes of Administration, H1 2018
Figure 10: Number of Products by Top 10 Molecule Types, H1 2018
Figure 11: Number of Products by Stage and Top 10 Molecule Types, H1 2018
Research Methodology
The research study released with title "Osteoporosis - Pipeline Review, H1 2018" involved the extensive usage of both primary and secondary data sources. The research process involved the study of various factors affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry, and market risks, opportunities, market barriers and challenges. The following illustrative figure shows the market research methodology applied in this report.Key Executives Interviewed
Research Programs/Design
| Historical Data (2017-2022E) |
|
|
| Market Factor Analysis |
|
|
| Market Forecast (2023F-2028F) |
|
|
Market Size Estimation
Top-down and bottom-up approaches are used to validate and estimate the global/regional market size by manufacturers, regional splits, product segments and application.
To establish Research coverage of the study with most relevant & functional players HTF MI follows industry standards such as NAICS/SIC/ICB/TRCB, furthermore the sorted list of companies is validated using Product Mapping and business activities and shortlisted by industry perspective.
HTF MI select experienced analyst and associate that are specialized in the domain for conducting research. They prepare a list of companies by region that helps to understand players penetration rate in the market. This companies are further analyses in what segment or application they serve in our market. The list of product and applications are evaluated for each companies dealing in the Osteoporosis Pipeline Review outlook. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global. Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Online) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc from Osteoporosis Pipeline Review outlook who then work towards appointment generation.
Primary Data Collection
The primary research is performed by taking the interviews of executives of various companies dealing in the Osteoporosis Pipeline Review outlook as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and relevant list of appointee or target primary respondents; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & In Mail, Community Forums, Open Survey, SurveyMonkey etc.
Secondary Sources
The secondary resources considered in the Osteoporosis Pipeline Review outlook study includes company annual reports, press releases, published articles of organizations and associations, and the survey taken through different mediums such as online website and forums, survey monkey, LinkedIn, etc. In addition, the valuable strategic information obtained from industry association, paid database, and investor presentations are also good tool for information to make appropriate iterative validation are used to modify market models and cross-verify primary research and insights.
Market Breakdown and Data Triangulation
To make market engineering data complete; extensive primary research is conducted to gather information and validate the critical numbers derived to be used for calculations of market statistics; market size estimations; forecasting; breakdown; and data triangulation. Both top-down and bottom-up approaches were applied, along with several data triangulation methods, to perform market estimation and market forecasting for the overall market segments and sub-segments listed in this report. Furthermore qualitative and further quantitative analysis is also done for all the numbers arrived at in the market estimation process to list relevant information in the final deliverable report "Osteoporosis - Pipeline Review, H1 2018" .
| Market Size |
|
|
| Market Position of Top Company |
|
|
| Qualitative Analysis |
|
|
Key Information from Primary Sources
| Primary Sources | Parameters | Key Data |
| Market Segments |
|
|
| Total Market |
|
|
| Format | Properties | |
|---|---|---|
| 1-User Access | The report is sent in PDF format. The report will be emailed to you. | This is a single user access license, allowing one specific user to access the report. |
| Site User | The study would be provided in PDF format. The report will be emailed to you. | This is a site license, allowing 1-10 employees within your organisation to access the report. |
| Enterprise User | The format of deliverable would be PDF and Excel. | This is an enterprise or corporate license, allowing all employees within your organisation irrespective of geographic location to access the report. |
